Crestchem reported a strong first quarter for fiscal year 2027, with standalone profits surging 180% to ₹0.98 crore and revenue up 82.4% to ₹9.18 crore year-on-year. The subsidiary, however, reported a loss.
Crestchem Reports Stellar Q1 FY27 Performance
Standalone profit for the quarter ended June 30, 2026, was ₹0.98 crore.
Standalone revenue from operations reached ₹9.18 crore.
Reader Takeaway: Strong standalone growth driven by revenue surge, but subsidiary loss presents a challenge.
What just happened
Crestchem Limited announced its financial results for the first quarter ended June 30, 2026. The company reported a standalone profit of ₹0.98 crore, a significant increase of 180% from ₹0.35 crore in the same quarter last year. Standalone revenue from operations surged by 82.4% to ₹9.18 crore, up from ₹5.03 crore in the prior year's quarter.
Why this matters
The strong year-over-year growth in both revenue and profit on a standalone basis indicates improving operational efficiency and market traction for Crestchem. This performance could be viewed positively by investors, demonstrating the company's ability to grow its core business. However, the performance of its subsidiary needs attention.
The backstory
Crestchem Limited operates within the Nutrition-Chemical Industries segment. The company's recent financial results reflect its performance in this sector. The consolidated results include the operations of its subsidiary, Oleo Biosciences Private Limited.
What changes now
With these strong standalone results, Crestchem demonstrates its growth potential. Investors will now look towards the company's ability to integrate and improve the performance of its subsidiary to achieve overall consolidated profitability.
Risks to watch
The primary risk highlighted is the continued loss-making status of the subsidiary, Oleo Biosciences Private Limited, which posted a net loss of ₹0.04 crore for the quarter. This could potentially offset gains made at the parent company level.
Peer comparison
(No peer comparison data available in the filing.)
Context metrics (time-bound)
Standalone revenue from operations for Q1 FY27 was ₹9.18 crore, an 82.4% increase from ₹5.03 crore in Q1 FY26.
Standalone profit for Q1 FY27 was ₹0.98 crore, a 180% increase from ₹0.35 crore in Q1 FY26.
Earnings Per Share (EPS) on a standalone basis was ₹3.28 for the quarter.
What to track next
Investors will be keen to monitor the progress of Oleo Biosciences Private Limited in turning profitable. Continued growth in standalone revenue and profit, alongside improvements in consolidated results, will be key factors to watch.